B
0.091
0.00 (-4.21%)
| Previous Close | 0.095 |
| Open | 0.095 |
| Volume | 155,271 |
| Avg. Volume (3M) | 515,844 |
| Market Cap | 33,303,088 |
| Price / Book | 3.33 |
| 52 Weeks Range |
| Profit Margin | -206.58% |
| Operating Margin (TTM) | -308.11% |
| Diluted EPS (TTM) | -0.030 |
| Quarterly Revenue Growth (YOY) | -33.00% |
| Total Debt/Equity (MRQ) | 17.74% |
| Current Ratio (MRQ) | 3.60 |
| Operating Cash Flow (TTM) | -4.52 M |
| Levered Free Cash Flow (TTM) | -3.61 M |
| Return on Assets (TTM) | -36.51% |
| Return on Equity (TTM) | -92.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | BCAL FPO [BDX] | - | - |
AIStockmoo Score
-0.5
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -1.0 |
| Average | -0.50 |
|
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 48.67% |
| % Held by Institutions | 3.55% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |